For example, selective RARβ antagonists may result in decreased skin toxicity by sparing RARγ. The combination with chromatin remodelling remains an appealing therapeutic strategy to restore sensitivity when retinoid resistance is due to epigenetic loss of RARβ2. We recognise that the assessment of RARβ2 expression/methylation in the tumour samples would have strengthened the results of our study. The gene discussed is RARB; the disease is neoplasm.